Bortezomib Plus Rituximab for EBV+ PTLD

Status Completed

Clinical Trial Summary

Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation. This is usually related to a virus called Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) to treat multiple myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the addition of bortezomib to rituximab treatment can increase the rate of complete remissions and cures of PTLD after organ or stem cell transplant.

Clinical Trial Description

- Both rituximab and bortezomib will be given to participants intravenously. Each cycle of treatment will consist of 21 days. Rituximab will be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles. Bortezomib will be given on Days 1, 4, 8 and 11 of every cycle. Participants will receive a maximum of 4 cycles.

- The following study procedures will be performed during each cycle throughout the study: Medical history review; Physical exam; Performance Status; Questionnaire; Blood draws and; PET/CT scans (After cycles 2, 4 and 6 only).

- After Cycle 4, if the study doctor feels the participant has had a complete response to treatment, then they will continue onto the Post-Treatment Surveillance period, which will consist of regular clinic visits over two years.

- However, if the study doctor feels the participant has had a partial response to treatment and that they may benefit from continuing, they will receive an additional two cycles of bortezomib and be given daily tablets of the antiviral drug valganciclovir to help further target EBV. ;

Study Design

Related Conditions & MeSH terms

Epstein Barr Virus Infections
Epstein-Barr Virus Infections
Lymphoproliferative Disorders
Post-transplant Lymphoproliferative Disease
Solid Organ Transplant
Stem Cell Transplant (Bone Marrow Transplant)
Virus Diseases

Clinical Trial Details

NCT number	NCT01058239
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	November 2011
Completion date	November 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03950414` - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients	Phase 1
Recruiting	`NCT05663463` - Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients	N/A
Completed	`NCT05124509` - Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
Completed	`NCT05121142` - Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease	Phase 1
Withdrawn	`NCT03327987` - Early Flu Shots in SOT
Completed	`NCT04253548` - iPeer2Peer Pediatric Thoracic Transplantation	N/A
Recruiting	`NCT05164016` - Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
Withdrawn	`NCT02464306` - Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection	Phase 4
Completed	`NCT02165423` - Discharge to Home and Chronic Illness Care Pilot	N/A
Completed	`NCT00907023` - Transition From Hospital to Home in Solid Organ Transplant (SOT)	N/A
Recruiting	`NCT04613206` - High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients	Phase 2
Recruiting	`NCT05550298` - Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
Completed	`NCT00518778` - Fusariosis in Solid-Organ Transplant Recipients	N/A
Active, not recruiting	`NCT04331275` - Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant	Phase 2
Recruiting	`NCT05968807` - iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients	N/A
Active, not recruiting	`NCT03482739` - Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients	Phase 3
Not yet recruiting	`NCT04721288` - REmote moBile Outpatient mOnitoring in Transplant 2.0	N/A
Completed	`NCT04844489` - Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People	N/A
Active, not recruiting	`NCT03360682` - Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.